NCT06730308

Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma

A Prospective, Single-arm Phase II Study of Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.

Detailed description

This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma. Patients will receive hypofractionated radiotherapy with concurrent chemotherapy. Methylprednisolone will be administered daily during radiotherapy at a dose of 2 mg/kg.

Conditions

• Thymoma

Interventions

Type	Name	Description
RADIATION	Radiotherapy	Hypofractionated radiotherapy
DRUG	Concurrent chemotherapy	weekly albumin-bound paclitaxel (50 mg/m²) and cisplatin (25 mg/m²)
DRUG	Methylprednisolone	Methylprednisolone 2mg/kg, qd, concurrent with radiotherapy

Timeline

• Start date: 2024-11-20
• Primary completion: 2028-11-19
• Completion: 2028-11-19
• First posted: 2024-12-12
• Last updated: 2024-12-12

Locations

1 site across 1 country: China